Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Caplin Point Laboratories's Marketable Securities for the quarter that ended in Mar. 2026 was ₹9,867 Mil.
Caplin Point Laboratories's annual Marketable Securities
increased
from Mar. 2024 (₹2,380 Mil) to Mar. 2025 (₹3,113 Mil) and
increased
from Mar. 2025 (₹3,113 Mil) to Mar. 2026 (₹9,867 Mil).
Caplin Point Laboratories (NSE:CAPLIPOINT) Marketable Securities Explanation
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
Caplin Point Laboratories Marketable Securities Related Terms
Caplin Point Laboratories Marketable Securities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caplin Point Laboratories Marketable Securities Chart
What does a Marketable Securities of ₹9,867 Mil mean?
Caplin Point Laboratories (NSE:CAPLIPOINT) has a Marketable Securities of ₹9,867 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Caplin Point Laboratories and its competitors.
Is Caplin Point Laboratories' Marketable Securities too high?
Caplin Point Laboratories' current Marketable Securities is ₹9,867 Mil. Overall, Caplin Point Laboratories has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' Marketable Securities compare to ZTS and UTHR?
Caplin Point Laboratories' Marketable Securities of ₹9,867 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Caplin Point Laboratories and its competitors. Caplin Point Laboratories's current Marketable Securities is ₹9,867 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,093.91, compared to a current price of ₹2,480.60 — trading 18.5% above its estimated fair value. The current Marketable Securities is ₹9,867 Mil. Caplin Point Laboratories' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current Marketable Securities is ₹9,867 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?
Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued.
The current stock price of ₹2,480.60 is trading 18.5% above its estimated GF Value™ of ₹2,093.91.
GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:CAPLIPOINT:
Marketable Securities: ₹9,867 Mil
GF Value™: ₹2,093.91 vs. price of ₹2,480.60 (18.5% above fair value)
No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
91GF Score
Get the complete analysis for NSE:CAPLIPOINT
Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CAPLIPOINT has been successfully added to your 
